MovDisordV3, Main, Exploration, bibRecord, 004A56

Illness impact and adjustment to Parkinson's disease: Before and after treatment with tolcapone

Identifieur interne : 004A56 ( Main/Exploration ); précédent : 004A55; suivant : 004A57

Illness impact and adjustment to Parkinson's disease: Before and after treatment with tolcapone

Auteurs : Mickie D. Welsh [États-Unis] ; Ernest Dorflinger [États-Unis] ; Doris Chernik [États-Unis] ; Cheryl Waters [États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 2000-05.

RBID : ISTEX:1BB0C2051011B6F41C43E2ACD27AD1AAD5D55DC9

Descripteurs français

Pascal (Inist)
- Catechol O-methyltransferase, Chimiothérapie, Homme, Impact social, Inhibiteur enzyme, Parkinson maladie, Tolcapone, Traitement.
Wicri :
- topic : Homme, Impact social.

English descriptors

KwdEn :
- Adaptation, Psychological, Adjustment to illness, Adult, Aged, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Benzophenones (adverse effects), Benzophenones (therapeutic use), Carbidopa (adverse effects), Carbidopa (therapeutic use), Catechol O-methyltransferase, Chemotherapy, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Enzyme inhibitor, Female, Human, Humans, Levodopa (adverse effects), Levodopa (therapeutic use), Male, Middle Aged, Nitrophenols, Parkinson Disease (drug therapy), Parkinson Disease (psychology), Parkinson disease, Parkinson's disease, Quality of Life, Sick Role, Sickness Impact Profile, Social impact, Tolcapone, Treatment, Treatment Outcome.
MESH :
- chemical , adverse effects : Antiparkinson Agents, Benzophenones, Carbidopa, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Benzophenones, Carbidopa, Levodopa.
- drug therapy : Parkinson Disease.
- psychology : Parkinson Disease.
- Adaptation, Psychological, Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Nitrophenols, Quality of Life, Sick Role, Sickness Impact Profile, Treatment Outcome.

Abstract

Research on the impact of disease and treatment on health status and quality of life in patients with movement disorders is limited. We studied quality of life in 46 patients with Parkinson's disease (PD) to determine whether the impact of illness and psychosocial adjustment to illness were improved by 42 days of adjunctive therapy with tolcapone (50 mg, 200 mg, or 400 mg three times a day). This study was conducted in parallel with a double‐blind, placebo‐controlled, dose‐response study of the safety and efficacy of tolcapone in combination with levodopa/carbidopa therapy. Only a subset of individuals from the larger study participated. In the quality of life study, illness impact and adjustment to illness were measured subjectively by the Sickness Impact Profile (SIP) and the Psychosocial Adjustment to Illness Scale‐Self‐Report (PAIS‐SR). Patient ratings of total illness impact (p = 0.003), physical illness impact (p = 0.05), and psychosocial illness impact (p = 0.007) improved significantly in individuals receiving tolcapone compared with those receiving placebo. There was no statistically significant difference in adjustment to illness when the tolcapone and placebo groups were compared; however, 17 of 21 adjustment to illness indicators showed improvement.

Url:

https://api.istex.fr/document/1BB0C2051011B6F41C43E2ACD27AD1AAD5D55DC9/fulltext/pdf

DOI: 10.1002/1531-8257(200005)15:3<497::AID-MDS1012>3.0.CO;2-4

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Illness impact and adjustment to Parkinson's disease: Before and after treatment with tolcapone</title>
<author><name sortKey="Welsh, Mickie D" sort="Welsh, Mickie D" uniqKey="Welsh M" first="Mickie D." last="Welsh">Mickie D. Welsh</name>
</author>
<author><name sortKey="Dorflinger, Ernest" sort="Dorflinger, Ernest" uniqKey="Dorflinger E" first="Ernest" last="Dorflinger">Ernest Dorflinger</name>
</author>
<author><name sortKey="Chernik, Doris" sort="Chernik, Doris" uniqKey="Chernik D" first="Doris" last="Chernik">Doris Chernik</name>
</author>
<author><name sortKey="Waters, Cheryl" sort="Waters, Cheryl" uniqKey="Waters C" first="Cheryl" last="Waters">Cheryl Waters</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:1BB0C2051011B6F41C43E2ACD27AD1AAD5D55DC9</idno>
<date when="2000" year="2000">2000</date>
<idno type="doi">10.1002/1531-8257(200005)15:3<497::AID-MDS1012>3.0.CO;2-4</idno>
<idno type="url">https://api.istex.fr/document/1BB0C2051011B6F41C43E2ACD27AD1AAD5D55DC9/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001996</idno>
<idno type="wicri:Area/Istex/Curation">001996</idno>
<idno type="wicri:Area/Istex/Checkpoint">003256</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Welsh M:illness:impact:and</idno>
<idno type="wicri:Area/Main/Merge">007353</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:00-0272223</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002B95</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000126</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002B93</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Welsh M:illness:impact:and</idno>
<idno type="wicri:Area/Main/Merge">007585</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:10830415</idno>
<idno type="wicri:Area/PubMed/Corpus">003F77</idno>
<idno type="wicri:Area/PubMed/Curation">003F77</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003F69</idno>
<idno type="wicri:Area/Ncbi/Merge">000274</idno>
<idno type="wicri:Area/Ncbi/Curation">000274</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000274</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Welsh M:illness:impact:and</idno>
<idno type="wicri:Area/Main/Merge">007112</idno>
<idno type="wicri:Area/Main/Curation">004A56</idno>
<idno type="wicri:Area/Main/Exploration">004A56</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Illness impact and adjustment to Parkinson's disease: Before and after treatment with tolcapone</title>
<author><name sortKey="Welsh, Mickie D" sort="Welsh, Mickie D" uniqKey="Welsh M" first="Mickie D." last="Welsh">Mickie D. Welsh</name>
<affiliation wicri:level="2"><country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>University of Southern California School of Medicine, Los Angeles</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Dorflinger, Ernest" sort="Dorflinger, Ernest" uniqKey="Dorflinger E" first="Ernest" last="Dorflinger">Ernest Dorflinger</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Hoffmann‐La Roche, Nutley</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Chernik, Doris" sort="Chernik, Doris" uniqKey="Chernik D" first="Doris" last="Chernik">Doris Chernik</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Hoffmann‐La Roche, Nutley</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Waters, Cheryl" sort="Waters, Cheryl" uniqKey="Waters C" first="Cheryl" last="Waters">Cheryl Waters</name>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Columbia University, New York, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
<settlement type="city">New York</settlement>
</placeName>
<orgName type="university">Université Columbia</orgName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>John Wiley & Sons, Inc.</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2000-05">2000-05</date>
<biblScope unit="vol">15</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="497">497</biblScope>
<biblScope unit="page" to="502">502</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">1BB0C2051011B6F41C43E2ACD27AD1AAD5D55DC9</idno>
<idno type="DOI">10.1002/1531-8257(200005)15:3<497::AID-MDS1012>3.0.CO;2-4</idno>
<idno type="ArticleID">MDS1012</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adaptation, Psychological</term>
<term>Adjustment to illness</term>
<term>Adult</term>
<term>Aged</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Benzophenones (adverse effects)</term>
<term>Benzophenones (therapeutic use)</term>
<term>Carbidopa (adverse effects)</term>
<term>Carbidopa (therapeutic use)</term>
<term>Catechol O-methyltransferase</term>
<term>Chemotherapy</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Drug Therapy, Combination</term>
<term>Enzyme inhibitor</term>
<term>Female</term>
<term>Human</term>
<term>Humans</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Nitrophenols</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (psychology)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Quality of Life</term>
<term>Sick Role</term>
<term>Sickness Impact Profile</term>
<term>Social impact</term>
<term>Tolcapone</term>
<term>Treatment</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Benzophenones</term>
<term>Carbidopa</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Benzophenones</term>
<term>Carbidopa</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adaptation, Psychological</term>
<term>Adult</term>
<term>Aged</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Nitrophenols</term>
<term>Quality of Life</term>
<term>Sick Role</term>
<term>Sickness Impact Profile</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Catechol O-methyltransferase</term>
<term>Chimiothérapie</term>
<term>Homme</term>
<term>Impact social</term>
<term>Inhibiteur enzyme</term>
<term>Parkinson maladie</term>
<term>Tolcapone</term>
<term>Traitement</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
<term>Impact social</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Research on the impact of disease and treatment on health status and quality of life in patients with movement disorders is limited. We studied quality of life in 46 patients with Parkinson's disease (PD) to determine whether the impact of illness and psychosocial adjustment to illness were improved by 42 days of adjunctive therapy with tolcapone (50 mg, 200 mg, or 400 mg three times a day). This study was conducted in parallel with a double‐blind, placebo‐controlled, dose‐response study of the safety and efficacy of tolcapone in combination with levodopa/carbidopa therapy. Only a subset of individuals from the larger study participated. In the quality of life study, illness impact and adjustment to illness were measured subjectively by the Sickness Impact Profile (SIP) and the Psychosocial Adjustment to Illness Scale‐Self‐Report (PAIS‐SR). Patient ratings of total illness impact (p = 0.003), physical illness impact (p = 0.05), and psychosocial illness impact (p = 0.007) improved significantly in individuals receiving tolcapone compared with those receiving placebo. There was no statistically significant difference in adjustment to illness when the tolcapone and placebo groups were compared; however, 17 of 21 adjustment to illness indicators showed improvement.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Californie</li>
<li>New Jersey</li>
<li>État de New York</li>
</region>
<settlement><li>New York</li>
</settlement>
<orgName><li>Université Columbia</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Californie"><name sortKey="Welsh, Mickie D" sort="Welsh, Mickie D" uniqKey="Welsh M" first="Mickie D." last="Welsh">Mickie D. Welsh</name>
</region>
<name sortKey="Chernik, Doris" sort="Chernik, Doris" uniqKey="Chernik D" first="Doris" last="Chernik">Doris Chernik</name>
<name sortKey="Dorflinger, Ernest" sort="Dorflinger, Ernest" uniqKey="Dorflinger E" first="Ernest" last="Dorflinger">Ernest Dorflinger</name>
<name sortKey="Waters, Cheryl" sort="Waters, Cheryl" uniqKey="Waters C" first="Cheryl" last="Waters">Cheryl Waters</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004A56 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004A56 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:1BB0C2051011B6F41C43E2ACD27AD1AAD5D55DC9
   |texte=   Illness impact and adjustment to Parkinson's disease: Before and after treatment with tolcapone
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Illness impact and adjustment to Parkinson's disease: Before and after treatment with tolcapone

Illness impact and adjustment to Parkinson's disease: Before and after treatment with tolcapone

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.